To evaluate whether the administration of therapeutic doses of paracetamol cause hepatic injury in the alcoholic patient.
Results of the review
Twenty-seven studies were included in the review: 7 Class I or II studies, and 20 Class III case reports for 25 patients.
Class I data (2 RCTs, n=260) showed that, compared with a placebo group, the repeated ingestion of a therapeutic dose of paracetamol over 48 hours by patients with severe alcoholism did not produce a deterioration on liver function tests nor any clinical manifestations.
Class II data (prospective, non-randomised trials, n=55) revealed that therapeutic doses of paracetamol have been administered to patients with an array of liver diseases (alcoholic, primary biliary, postnecrotic, or unspecified cirrhosis or alcoholic, acute viral, chronic active, or other infectious hepatitis) for periods up to 14 days without an adverse effect. In several further studies, a 1 to 2 g single dose of paracetamol was administered to alcoholic patients to study metabolism, again without any adverse effects.
Class III data (retrospective case reviews and case reports) described hepatic injury after repeated paracetamol ingestion with therapeutic intent, although usually not at therapeutic doses. The information from these studies was often incomplete and contradictory.
Authors' conclusions
All the methodologically sound studies available indicated that the therapeutic dosing of paracetamol to the alcoholic patient was not associated with hepatic injury. There was no change in hepatic aminotransferase enzymes, prothrombin time, or other biochemical parameters when compared with a placebo group in well-designed trials. Unless stronger evidence of a potentially dangerous interaction emerges, the use of paracetamol in the alcoholic patient is reasonable.
CRD commentary
This systematic review stated a clear research question, although some of the inclusion and exclusion criteria were not predefined by the authors. The literature search was limited and could have looked at additional databases. While there were no language restrictions on the search, the authors did not assess publication bias or search for unpublished literature.
The studies were assessed for quality using a grading system rather than a scoring of methodological quality. Apart from the data extraction, the authors did not state who performed the study selection or validity assessment processes for the review. It would appears that only one author extracted the data, and the data were not checked by any of the other authors.
The results were combined in a narrative review since the data for a statistical meta-analysis were unavailable. There was very little discussion of the differences between the studies, although the quality was incorporated into the discussion of the included studies.
Overall, the authors' conclusions appear to follow from the data presented. Readers should take note of the different outcomes from the more reliable findings in the Class I and II studies, compared with the lower-quality nonrandomised and non-controlled Class III case reports.
